FPI-2265 (225Ac-PSMA-I&T) for Patients With PSMA-Positive Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Clinical Trials, Intermediate Risk Prostate Cancer, Low Risk Prostate Cancer

— PHENTrials.com Increasing Participation in Prostate Cancer Clinical Trials to Save Lives

NCT Number: NCT06402331
Phase: PHASE2|PHASE3
Trial Summary: This is an open-label, randomized, multicenter study of FPI-2265 (225Ac-PSMA-I&T). The dose optimization Phase 2 part will be investigating the safety, tolerability, and anti-tumor activity of novel – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): Fusion Pharmaceuticals Inc.
Acronym: AlphaBreak

Pin It on Pinterest